Kidney dysfunction during lenalidomide treatment for AL amyloidosis | Zendy

R. Specter | Zendy; Vaishali Sanchorawala | Zendy; David C. Seldin | Zendy; Anthony C Shelton | Zendy; Salli Fennessey | Zendy; Kyle Finn | Zendy; Jerome B. Zeldis | Zendy; Laura M. Dember | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Kidney dysfunction during lenalidomide treatment for AL amyloidosis

Author(s) -

R. Specter,

Vaishali Sanchorawala,

David C. Seldin,

Anthony C Shelton,

Salli Fennessey,

Kyle Finn,

Jerome B. Zeldis,

Laura M. Dember

Publication year - 2010

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfq482

Subject(s) - medicine , lenalidomide , renal function , creatinine , amyloidosis , kidney , dialysis , urology , al amyloidosis , kidney disease , gastroenterology , multiple myeloma , immunology , antibody , immunoglobulin light chain

Lenalidomide is an immunomodulatory agent used to treat plasma cell dyscrasias. We previously observed worsening of kidney function in a high proportion of patients with AL amyloidosis during lenalidomide treatment. The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research